Search results
Regeneron is a biotech company that develops new medicines for serious diseases, such as cancer, asthma and COVID-19. Learn about their scientific breakthroughs, clinical trials, responsibility goals and career opportunities.
- Scientists
Rapid response to infectious diseases. How can we go even...
- Patients
Compassionate use: Access to investigational medicines....
- Medical Professionals
Regeneron’s Compassionate Use Policy gives certain patients...
- Investors and Media
We are a leading science and technology company that...
- Careers
Working at Regeneron. We are a team of original thinkers who...
- Find Trials
Regeneron is a biotechnology company that develops medicines...
- Improving Lives
Regeneron has supported advocacy training, distribution of...
- About
At Regeneron, we move science to medicine because our world...
- Scientists
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Regeneron is a biotech company that invents and develops medicines for serious diseases, such as eye, allergic, inflammatory, cancer, and rare diseases. Founded and led by physician-scientists, Regeneron uses proprietary technologies and genetics sequencing to create life-transforming treatments.
Find the latest Regeneron Pharmaceuticals, Inc. (REGN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Regeneron is a global biopharmaceutical company that invents, develops and commercializes life-transforming medicines for serious diseases. Follow its LinkedIn page to learn about its culture, science, careers and events.
Regeneron is leading the way, developing new technologies to help discover better and novel antibody medicines. While most of our approved medicines are fully human monoclonal antibodies, we are exploring newer types of antibody medicines, including bispecific antibodies and antibody drug conjugates (ADCs).